Trial: Targeted Treatment for Advanced Non-Sma…

Trial Details

Sponsor: SWOG Cancer Research Network (federal)

Phase: 2

Start date: Nov. 3, 2023

Planned enrollment: 88

Last updated in HealthScout: Nov 2024

Show Summary from Sponsor

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-vmjw works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-vmjw is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-vmjw may lower the chance of the growth or spread of advanced non-small cell lung cancer that has extra copies of the MET gene in the tumor.

More details:

PRIMARY OBJECTIVE: I. To evaluate the objective response rate (ORR) (confirmed and unconfirmed, complete and partial) in participants with MET amplification-positive non-small cell lung cancer (NSCLC) treated with amivantamab (amivantamab-vmjw) within each cohort. SECONDARY OBJECTIVES: I. To evaluate progression-free survival (PFS) within each cohort. II. To evaluate overall survival (OS) within each cohort. III. To evaluate the duration of response among responders within each cohort. IV. To evaluate the frequency and severity of toxicities within each cohort and combined across all study participants. TRANSLATIONAL MEDICINE OBJECTIVES: I. To collect, process, and bank cell-free deoxyribonucleic acid (cfDNA) prior to treatment on Cycle 1 Day 1, Cycle 3 Day 1, and at first progression for future development of a proposal to evaluate comprehensive next-generation sequencing of circulating tumor deoxyribonucleic acid (ctDNA). II. To establish a tissue/blood repository from participants with refractory non-small cell lung cancer (NSCLC). OUTLINE: Patients receive amivantamab intravenously (IV) on days 1 and 2 in week and once a week in weeks 2-4 of cycle 1 and then on days 1 and 15 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computerized tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial. After completion of study treatment, patients are followed up for up to 3 years.

Investigational Drug AI Analysis

No investigational drugs.

More Resources

Trial ID: NCT06116682

More trial details at ClinicalTrials.gov

Show News & AI Analysis

HealthScout AI Analysis

Goal: To evaluate the efficacy of amivantamab-vmjw in improving objective response rates and survival outcomes in patients with MET amplification-positive non-small cell lung cancer (NSCLC).

Patients: The trial is focused on individuals diagnosed with stage IV or recurrent non-small cell lung cancer with MET amplification. Eligible participants require measurable disease and must have progressed following previous treatments. Exclusion criteria include known actionable oncogenic alterations, previous treatment with MET tyrosine kinase inhibitors, and recent exposure to other chemotherapy, etc.

Design: This is a non-randomized, single-arm Phase II trial, specifically targeting a subset of NSCLC patients identified through the Expanded Lung-MAP platform.

Treatments: Participants receive Amivantamab-vmjw, a bispecific antibody targeting EGFR and MET receptors, intravenously, initially over two days and subsequently every two weeks. This investigational drug may reduce tumor growth by targeting MET amplification, a known contributor to cancer proliferation. Early trials indicate its potential effectiveness in NSCLC with this specific genetic alteration.

Outcomes: The primary outcome is the objective response rate. Key secondary outcomes include overall survival, progression-free survival, duration of response, and the incidence and severity of treatment-related toxicities.

Burden on patient: The burden on patients is moderate. Participants undergo regular intravenous administration of amivantamab, with treatment cycles extending indefinitely unless disease progression or unacceptable toxicity occurs. Frequent imaging assessments (CT or MRI) and blood sample collections are required throughout the study for comprehensive monitoring of treatment impact, imposing additional logistical and time commitments compared to standard care.

Eligibility Criteria

Show Criteria

Inclusion Criteria:

* Participants must have been assigned to S1900J by the Southwest Oncology Group (SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900J is determined by the LUNGMAP protocol

* Participants must have documentation of NSCLC with MET amplification determined by FMI tissue-based next generation sequencing (NGS) assay

* Participants must have measurable disease documented by CT or MRI. The CT from a combined positron emission tomography (PET)/CT may be used to document measurable disease ONLY if it is of diagnostic quality: otherwise, it may be used to document non-measurable disease only. Measurable disease must be assessed within 28 days prior to sub-study registration. Pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease. Non-measurable disease must be assessed within 42 days prior to sub-study registration. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form. Participants whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to sub-study registration to be considered measurable

* Participants must have a CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease within 42 days prior to sub-study registration

* Participants with asymptomatic CNS metastasis (brain metastases or leptomeningeal disease) must be clinically stable and asymptomatic for at least 14 days prior to sub-study registration

* NOTE: Participants can be on a low-dose corticosteroid treatment (≤ 10 mg prednisone or equivalent) for at least 14 days prior to study treatment

* Participants must not have other known actionable oncogenic alterations, such as (but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, MET Exon-14 skipping mutant NSCLC, ALK gene fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2 mutation, KRAS activating mutations, and BRAF V600E mutation

* Participants must have progressed (in the opinion of the treating physician) following the most recent line of therapy

* Participants must have received at least one line of systemic treatment for Stage IV or recurrent NSCLC

* Participants must have recovered (≤ Grade 1) from any side effects of prior therapy. The exception is if a side effect from a prior treatment is known to be permanent without expected further recovery or resolution (i.e., endocrinopathy from immunotherapy or cisplatin neurotoxicity)

* Participants must not have been previously treated for any cancer with MET tyrosine kinase inhibitors (TKIs) such as tepotinib, capmatinib, and crizotinib

* Participants must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to sub-study registration

* Participants must not have a prior treatment with anti-PD-1 or anti-PD-L1 antibody within 6 weeks of sub-study registration

* Participants must not have received any radiation therapy within 14 days prior to sub-study registration

* Participants must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment while receiving treatment on this study

* Participants must not have had major surgery excluding placement of vascular access or tumor biopsy, or had significant traumatic injury within 28 days prior to sub-study registration, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study

* NOTE: Participants with planned surgical procedures to be conducted under local anesthesia may participate

* Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the investigational regimen

* Absolute neutrophil count ≥ 1.5 x 10\^3/uL (within 28 days prior to sub-study registration)

* Hemoglobin \>= 10.0 g/dL (within 28 days prior to sub-study registration)

* Platelets ≥ 75 x 10\^3/uL (within 28 days prior to sub-study registration)

* Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin ≤ 5 x institutional ULN (within 28 days prior to sub-study registration)

* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × institutional ULN. Participants with history of liver metastasis must have AST and ALT ≤ 5 x ULN (within 28 days prior to sub-study registration)

* Participants must have a serum creatinine ≤ the institutional upper limit of normal (IULN) or calculated creatinine clearance ≥ 45 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to sub-study registration. For creatinine clearance formula see the tools on the CRA Workbench

* Participants' most recent Zubrod performance status must be 0-2 and be documented within 28 days prior to sub-study registration

* Participants must have a completed medical history and physical exam within 28 days prior to sub-study registration

* Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better

* Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy and have undetectable viral load test on the most recent test results obtained within 6 months prior to sub-study registration

* Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to sub-study registration

* Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to sub-study registration

* Participants with known diabetes as determined by the treating investigator must show evidence of controlled disease within 14 days prior to sub-study registration

* Participants of reproductive potential must have a negative serum pregnancy test within 7 days prior to sub-study registration

* Participants must not have other clinically active infectious liver disease

* Participants must not have clinically significant hypertension within 28 days prior to sub-study registration as determined by the treating investigator

* Participants must not have a history of pneumonitis that required drug therapy or an active symptomatic interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis

* Participants must not have ongoing or active infection or be diagnosed or suspected viral infection as determined by the treating investigator. NOTE: Participants that have an infection requiring antimicrobial therapy will be required to complete antibiotics 1 week prior to starting treatment

* Participants must not have active bleeding diathesis as determined by the treating investigator

* Participants must not have impaired oxygenation requiring continuous oxygen supplementation as determined by the treating investigator

* Participants must not have psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements as determined by the treating investigator

* Participants must not have any ophthalmologic condition that is unstable in the opinion of the treating investigator

* Participants must not be pregnant or breastfeeding (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped). Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

* Participants must agree to have blood specimens submitted for circulating tumor DNA (ctDNA)

* Participants must also be offered participation in specimen banking. With participant consent, specimens must be collected and submitted via the SWOG Specimen Tracking System

* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

* NOTE: Participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations

Sites (99)

Sort by distance to:

University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

No email / 501-686-8274

Status: Recruiting

Sutter Auburn Faith Hospital

Auburn, California, 95602, United States

[email protected] / No phone

Status: Recruiting

Alta Bates Summit Medical Center-Herrick Campus

Berkeley, California, 94704, United States

[email protected] / No phone

Status: Recruiting

Palo Alto Medical Foundation-Fremont

Fremont, California, 94538, United States

[email protected] / No phone

Status: Recruiting

Memorial Medical Center

Modesto, California, 95355, United States

[email protected] / No phone

Status: Recruiting

Palo Alto Medical Foundation Health Care

Palo Alto, California, 94301, United States

[email protected] / No phone

Status: Recruiting

Sutter Roseville Medical Center

Roseville, California, 95661, United States

[email protected] / No phone

Status: Recruiting

California Pacific Medical Center-Pacific Campus

San Francisco, California, 94115, United States

[email protected] / No phone

Status: Recruiting

Sutter Pacific Medical Foundation

Santa Rosa, California, 95403, United States

[email protected] / 415-209-2683

Status: Recruiting

Palo Alto Medical Foundation-Sunnyvale

Sunnyvale, California, 94086, United States

[email protected] / No phone

Status: Recruiting

Sutter Solano Medical Center/Cancer Center

Vallejo, California, 94589, United States

[email protected] / No phone

Status: Recruiting

Bayhealth Hospital Kent Campus

Dover, Delaware, 19901, United States

[email protected] / 302-674-4401

Status: Recruiting

Bayhealth Hospital Sussex Campus

Milford, Delaware, 19963, United States

[email protected] / 302-674-4401

Status: Recruiting

Northeast Georgia Medical Center-Gainesville

Gainesville, Georgia, 30501, United States

[email protected] / 770-219-8800

Status: Recruiting

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706, United States

[email protected] / 734-712-3671

Status: Recruiting

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605, United States

[email protected] / 734-712-3671

Status: Recruiting

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814, United States

[email protected] / 406-969-6060

Status: Recruiting

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687, United States

[email protected] / 406-969-6060

Status: Recruiting

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854, United States

[email protected] / 406-969-6060

Status: Recruiting

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864, United States

[email protected] / 406-969-6060

Status: Recruiting

Illinois CancerCare-Bloomington

Bloomington, Illinois, 61704, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Canton

Canton, Illinois, 61520, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Carthage

Carthage, Illinois, 62321, United States

[email protected] / 309-243-3605

Status: Recruiting

Carle at The Riverfront

Danville, Illinois, 61832, United States

[email protected] / 800-446-5532

Status: Recruiting

Cancer Care Specialists of Illinois - Decatur

Decatur, Illinois, 62526, United States

[email protected] / 217-876-4762

Status: Recruiting

Decatur Memorial Hospital

Decatur, Illinois, 62526, United States

[email protected] / 217-876-4762

Status: Recruiting

Carle Physician Group-Effingham

Effingham, Illinois, 62401, United States

[email protected] / 800-446-5532

Status: Recruiting

Crossroads Cancer Center

Effingham, Illinois, 62401, United States

[email protected] / 217-876-4762

Status: Recruiting

Illinois CancerCare-Eureka

Eureka, Illinois, 61530, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Galesburg

Galesburg, Illinois, 61401, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Kewanee Clinic

Kewanee, Illinois, 61443, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Macomb

Macomb, Illinois, 61455, United States

[email protected] / 309-243-3605

Status: Recruiting

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938, United States

[email protected] / 800-446-5532

Status: Recruiting

SSM Health Good Samaritan

Mount Vernon, Illinois, 62864, United States

[email protected] / 618-899-1894

Status: Recruiting

Cancer Care Center of O'Fallon

O'Fallon, Illinois, 62269, United States

[email protected] / 217-876-4762

Status: Recruiting

Illinois CancerCare-Ottawa Clinic

Ottawa, Illinois, 61350, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Pekin

Pekin, Illinois, 61554, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Peoria

Peoria, Illinois, 61615, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Peru

Peru, Illinois, 61354, United States

[email protected] / 309-243-3605

Status: Recruiting

Illinois CancerCare-Princeton

Princeton, Illinois, 61356, United States

[email protected] / 309-243-3605

Status: Recruiting

Southern Illinois University School of Medicine

Springfield, Illinois, 62702, United States

No email / 217-545-7929

Status: Recruiting

Springfield Clinic

Springfield, Illinois, 62702, United States

No email / 800-444-7541

Status: Recruiting

Springfield Memorial Hospital

Springfield, Illinois, 62781, United States

[email protected] / 217-528-7541

Status: Recruiting

Carle Cancer Center

Urbana, Illinois, 61801, United States

[email protected] / 800-446-5532

Status: Recruiting

Illinois CancerCare - Washington

Washington, Illinois, 61571, United States

[email protected] / 309-243-3605

Status: Recruiting

Mary Greeley Medical Center

Ames, Iowa, 50010, United States

No email / 515-956-4132

Status: Recruiting

McFarland Clinic - Ames

Ames, Iowa, 50010, United States

[email protected] / 515-239-4734

Status: Recruiting

McFarland Clinic - Boone

Boone, Iowa, 50036, United States

No email / 515-956-4132

Status: Recruiting

McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501, United States

No email / 515-956-4132

Status: Recruiting

McFarland Clinic - Jefferson

Jefferson, Iowa, 50129, United States

No email / 515-956-4132

Status: Recruiting

McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158, United States

No email / 515-956-4132

Status: Recruiting

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536, United States

No email / 859-257-3379

Status: Recruiting

Lafayette Family Cancer Center-EMMC

Brewer, Maine, 04412, United States

No email / 800-987-3005

Status: Recruiting

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118, United States

[email protected] / 734-712-7251

Status: Recruiting

Cancer Hematology Centers - Flint

Flint, Michigan, 48503, United States

[email protected] / 810-762-8038

Status: Recruiting

Genesee Hematology Oncology PC

Flint, Michigan, 48503, United States

[email protected] / 810-762-8038

Status: Recruiting

Genesys Hurley Cancer Institute

Flint, Michigan, 48503, United States

[email protected] / 810-762-8038

Status: Recruiting

Hurley Medical Center

Flint, Michigan, 48503, United States

[email protected] / 810-762-8038

Status: Recruiting

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912, United States

[email protected] / 517-364-3712

Status: Recruiting

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154, United States

[email protected] / 734-712-7251

Status: Recruiting

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197, United States

[email protected] / 734-712-7251

Status: Recruiting

Baptist Memorial Hospital and Cancer Center-Golden Triangle

Columbus, Mississippi, 39705, United States

[email protected] / 901-226-1366

Status: Recruiting

Baptist Cancer Center-Grenada

Grenada, Mississippi, 38901, United States

[email protected] / 901-226-1366

Status: Recruiting

Baptist Memorial Hospital and Cancer Center-Union County

New Albany, Mississippi, 38652, United States

[email protected] / 901-226-1366

Status: Recruiting

Baptist Memorial Hospital and Cancer Center-Oxford

Oxford, Mississippi, 38655, United States

[email protected] / 901-226-1366

Status: Recruiting

Baptist Memorial Hospital and Cancer Center-Desoto

Southhaven, Mississippi, 38671, United States

[email protected] / 901-226-1366

Status: Recruiting

Saint Francis Medical Center

Cape Girardeau, Missouri, 63703, United States

[email protected] / 573-334-2230

Status: Recruiting

Parkland Health Center - Farmington

Farmington, Missouri, 63640, United States

No email / 314-996-5569

Status: Recruiting

Sainte Genevieve County Memorial Hospital

Sainte Genevieve, Missouri, 63670, United States

No email / 314-996-5569

Status: Recruiting

Missouri Baptist Sullivan Hospital

Sullivan, Missouri, 63080, United States

No email / 314-996-5569

Status: Recruiting

BJC Outpatient Center at Sunset Hills

Sunset Hills, Missouri, 63127, United States

No email / 314-996-5569

Status: Recruiting

Billings Clinic Cancer Center

Billings, Montana, 59101, United States

[email protected] / 800-996-2663

Status: Recruiting

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715, United States

[email protected] / 406-969-6060

Status: Recruiting

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405, United States

[email protected] / 406-969-6060

Status: Recruiting

Community Medical Center

Missoula, Montana, 59804, United States

[email protected] / 406-969-6060

Status: Recruiting

OptumCare Cancer Care at Seven Hills

Henderson, Nevada, 89052, United States

[email protected] / 702-384-0013

Status: Recruiting

OptumCare Cancer Care at Charleston

Las Vegas, Nevada, 89102, United States

[email protected] / 702-384-0013

Status: Recruiting

OptumCare Cancer Care at Fort Apache

Las Vegas, Nevada, 89148, United States

[email protected] / 702-384-0013

Status: Recruiting

New Hampshire Oncology Hematology PA-Concord

Concord, New Hampshire, 03301, United States

No email / 603-224-2556

Status: Recruiting

Solinsky Center for Cancer Care

Manchester, New Hampshire, 03103, United States

No email / 800-339-6484

Status: Recruiting

ProMedica Flower Hospital

Sylvania, Ohio, 43560, United States

[email protected] / 419-824-1842

Status: Recruiting

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

[email protected] / 405-271-8777

Status: Recruiting

Providence Newberg Medical Center

Newberg, Oregon, 97132, United States

[email protected] / 503-215-2614

Status: Recruiting

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914, United States

[email protected] / 406-969-6060

Status: Recruiting

Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045, United States

[email protected] / 503-215-2614

Status: Recruiting

Providence Portland Medical Center

Portland, Oregon, 97213, United States

[email protected] / 503-215-2614

Status: Recruiting

Providence Saint Vincent Medical Center

Portland, Oregon, 97225, United States

[email protected] / 503-215-2614

Status: Recruiting

WellSpan Medical Oncology and Hematology

Chambersburg, Pennsylvania, 17201, United States

No email / 717-217-6020

Status: Recruiting

Ephrata Cancer Center

Ephrata, Pennsylvania, 17522, United States

No email / 717-721-4840

Status: Recruiting

Adams Cancer Center

Gettysburg, Pennsylvania, 17325, United States

No email / 877-441-7957

Status: Recruiting

Sechler Family Cancer Center

Lebanon, Pennsylvania, 17042, United States

[email protected] / 717-741-8303

Status: Recruiting

Cancer Care Associates of York

York, Pennsylvania, 17403, United States

No email / 717-741-9229

Status: Recruiting

Baptist Memorial Hospital and Cancer Center-Collierville

Collierville, Tennessee, 38017, United States

[email protected] / 901-226-1366

Status: Recruiting

Baptist Memorial Hospital and Cancer Center-Memphis

Memphis, Tennessee, 38120, United States

[email protected] / 901-226-1366

Status: Recruiting

Edwards Comprehensive Cancer Center

Huntington, West Virginia, 25701, United States

[email protected] / 304-399-6566

Status: Recruiting

West Virginia University Healthcare

Morgantown, West Virginia, 26506, United States

[email protected] / 304-293-7374

Status: Recruiting

A Phase II Study of Amivantamab in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

More Resources

Show News & AI Analysis

HealthScout AI Analysis

Eligibility Criteria

Show Criteria

Sites (99)

University of Arkansas for Medical Sciences

Sutter Auburn Faith Hospital

Alta Bates Summit Medical Center-Herrick Campus

Palo Alto Medical Foundation-Fremont

Memorial Medical Center

Palo Alto Medical Foundation Health Care

Sutter Roseville Medical Center

California Pacific Medical Center-Pacific Campus

Sutter Pacific Medical Foundation

Palo Alto Medical Foundation-Sunnyvale

Sutter Solano Medical Center/Cancer Center

Bayhealth Hospital Kent Campus

Bayhealth Hospital Sussex Campus

Northeast Georgia Medical Center-Gainesville

Saint Alphonsus Cancer Care Center-Boise

Saint Alphonsus Cancer Care Center-Caldwell

Kootenai Health - Coeur d'Alene

Saint Alphonsus Cancer Care Center-Nampa

Kootenai Clinic Cancer Services - Post Falls

Kootenai Clinic Cancer Services - Sandpoint

Illinois CancerCare-Bloomington

Illinois CancerCare-Canton

Illinois CancerCare-Carthage

Carle at The Riverfront

Cancer Care Specialists of Illinois - Decatur

Decatur Memorial Hospital

Carle Physician Group-Effingham

Crossroads Cancer Center

Illinois CancerCare-Eureka

Illinois CancerCare-Galesburg

Illinois CancerCare-Kewanee Clinic

Illinois CancerCare-Macomb

Carle Physician Group-Mattoon/Charleston

SSM Health Good Samaritan

Cancer Care Center of O'Fallon

Illinois CancerCare-Ottawa Clinic

Illinois CancerCare-Pekin

Illinois CancerCare-Peoria

Illinois CancerCare-Peru

Illinois CancerCare-Princeton

Southern Illinois University School of Medicine

Springfield Clinic

Springfield Memorial Hospital

Carle Cancer Center

Illinois CancerCare - Washington

Mary Greeley Medical Center

McFarland Clinic - Ames

McFarland Clinic - Boone

McFarland Clinic - Trinity Cancer Center

McFarland Clinic - Jefferson

McFarland Clinic - Marshalltown

University of Kentucky/Markey Cancer Center

Lafayette Family Cancer Center-EMMC

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Trinity Health IHA Medical Group Hematology Oncology - Canton

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Cancer Hematology Centers - Flint

Genesee Hematology Oncology PC

Genesys Hurley Cancer Institute

Hurley Medical Center

University of Michigan Health - Sparrow Lansing

Trinity Health Saint Mary Mercy Livonia Hospital

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Baptist Memorial Hospital and Cancer Center-Golden Triangle

Baptist Cancer Center-Grenada

Baptist Memorial Hospital and Cancer Center-Union County

Baptist Memorial Hospital and Cancer Center-Oxford

Baptist Memorial Hospital and Cancer Center-Desoto